Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments

Regency Pharma 筹集3000万美元用于神经功能恢复治疗

2020-03-26 13:30:10 Xconomy

本文共1549个字,阅读需4分钟

March 25th, 2020 Xconomy Boston —  Regenacy Pharmaceuticals, a biotech formed as part of Celgene’s acquisition of Acetylon Pharmaceuticals in late 2016, has raised $30 million in Series A financing to move its lead program into a Phase 2 proof-of-concept trial this year. The Waltham, MA-based company is developing treatments to address the underlying cause of peripheral neuropathies—a form of nerve damage in the fingers and toes that causes numbness and tingling—associated with diabetes and other conditions. Regenacy plans to first evaluate its lead drug candidate, ricolinostat, in diabetic peripheral neuropathy. Nerve damage caused by diabetes is a common and serious complication of both type 1 and type 2 diabetes, affecting as many as half of all diabetes patients. Regenacy estimates more than 200 million people with diabetes worldwide experience signs or symptoms of the condition, which can include numbness or reduced ability to feel pain or temperature changes, tingling or burning sensations, sharp pains or cramps, increased sensitivity to touch, and serious foot problems, such as ulcers, infections, and bone and joint pain. In addition to impacting quality of life, diabetic peripheral neuropathy can increase patients’ risk of limb amputation, according to the company. No approved treatments for the condition target its underlying causes or address associated numbness, and drugs typically used to manage nerve pain and other symptoms come with the risks of side effects. While the reason people with diabetes experience nerve damage is unknown, researchers think that uncontrolled high blood sugar may over time cause deterioration that interferes with nerves’ ability to send signals. Regenacy’s ricolinostat is an experimental oral medicine designed to selectively block histone deacetylase 6 (HDAC6), an enzyme that, if inhibited, Regenacy believes will let nerve cells better regulate the microtubules that play a key role in moving substances within the cell. When that transport function is disrupted, nerve cells can malfunction and send random signals or no signal at all. The company believes blocking HDAC6 could help cells reestablish that ability to appropriately transport substances and in doing so, reverse peripheral neuropathy symptoms and restore nerve fibers. The company also plans to study ricolinostat as a potential treatment for peripheral neuropathy caused by chemotherapy and peripheral neuropathy resulting from Charcot-Marie-Tooth disease type 2. Regenacy has other investigational drugs designed to target the HDAC class of enzymes in its preclinical pipeline as potential treatments for major blood diseases such as leukemia, sickle cell disease, beta thalassemia, and cognitive dysfunction in neurological disorders. Regenacy is headed by CEO Simon Jones, who started with the company as chief operating officer and senior vice president of preclinical development when it spun out and was appointed chief executive in mid-2017. Acetylon’s deal with Celgene, now part of Bristol Myers Squibb (NYSE: BMY), gave the pharma giant the rights to ricolinostat and another of its drug candidates, citarinostat, for cancer, neurodegenerative diseases, and autoimmune diseases. Regenacy kept the rights to the two drugs for other disease types, including nerve pain. Cobro Ventures and Taiwania Capital Management led Regenacy’s Series A financing round. 3E Bioventures Capital, Yonjin Capital, Viva Biotech Holdings, Ta Ya Venture, and undisclosed private investors participated. As part of the deal, Taiwania managing partner Michael Huang, 3E operating partner Frank Yan, and Yonjin managing director Daguang Wang join Regenacy’s board of directors. Image: iStock/kckate16 Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com. Follow @sarahdc
2020年3月25日 锥形经济 波士顿-- Regency Pharmaceuticals 是新基(Celgene)于2016年底收购 Acylon Pharmaceuticals 的一部分而组建的生物技术公司,该公司已筹集到3千万美元的 A 系列融资,以将其主导项目转入今年的第二阶段概念验证试验。 总部位于马萨诸塞州沃尔瑟姆的公司正在开发治疗方法,以解决外周神经病变的根本原因——一种导致手指和脚趾麻木和刺痛的神经损伤形式——与糖尿病和其他疾病有关。 Regency 计划首先评估其在糖尿病性周围神经病变中的主要候选药物——利可霉素。 糖尿病引起的神经损害是1型和2型糖尿病的常见和严重并发症,影响多达一半的糖尿病患者。据 Regency 估计,全球有2亿多糖尿病患者出现症状或体征,包括麻木或感觉疼痛或温度变化的能力降低、刺痛或灼伤感觉、剧烈疼痛或痉挛、对触摸的敏感性增强以及严重的足部问题,如溃疡、感染、骨关节疼痛。该公司表示,除了影响生活质量之外,糖尿病周围神经病变还会增加患者截肢的风险。 没有批准的治疗条件的目标是其潜在的原因或解决相关的麻木,药物通常用于管理神经痛和其他症状与风险的副作用。虽然糖尿病患者经历神经损伤的原因尚不清楚,但研究人员认为,不受控制的高血糖可能会随着时间的推移导致病情恶化,从而干扰神经发出信号的能力。 Regency 公司的 ricolistatat 是一种实验性的口服药物,旨在选择性阻断组蛋白去乙酰化酶6( HDAC6),一种酶,如果被抑制, Regency 公司相信将让神经细胞更好地调节微管,这些微管在细胞内运动物质中起关键作用。当运输功能中断时,神经细胞就会发生故障,发出随机信号或根本没有信号。该公司认为,阻断 HDAC6可以帮助细胞重建适当传输物质的能力,从而扭转周围神经病变的症状并恢复神经纤维。 该公司还计划研究利托伐他汀作为治疗因 Charcot-Marie-Tooth 病2型引起的化疗和外周神经病变的潜在治疗药物。Regency 还有其他研究药物,旨在针对其临床前管道中的 HDAC 类酶,作为治疗白血病、镰状细胞病、β-地中海贫血和神经系统疾病的认知功能障碍等主要血液疾病的潜在疗法。 Regency 由首席执行官西蒙•琼斯( Simon Jones )领导,他在公司上市时开始担任首席运营官和临床前开发高级副总裁,并于2017年年中被任命为首席执行官。Acylton 与新基(Celgene)的交易,现在是 Bristol Myers 施贵宝(Squibb)(纽约证券交易所: BMY )的一部分,使这家制药巨头有权获得 ricoliostat 和它的另一个候选药物, citarinostot ,用于治疗癌症、神经退行性疾病和自身免疫性疾病。Regency 保留这两种药物用于其他疾病类型的权利,包括神经疼痛。 Cobro Ventures 和 Taiwania Capital Management 领导了 Regency 的 A 轮融资。3E BioVentures Capital 、 Yonjin Capital 、 Viva Biotech Holdings 、 Ta Ya Venture 、未披露的私人投资者参与。作为交易的一部分,台湾网元的执行合伙人 Michael Huang 、3E 的运营合伙人 Frank Yan 和 Yonjin 的董事总经理 Da光 Wang 加入了 Regency 的董事会。 图像: iStock / kckpacte16 Sarah de Crescenzo 是位于圣地亚哥的 Xconomic 编辑。你可以在 sdecrescenzo @ xconomi.com 上联系她。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文